244767-67-7 | 4-({4-[(2,4,6-trimethylphenyl)amino]pyrimidin-2-yl}amino)benzonitrile

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$7.00	$5.00
5mg	98%	in stock	$12.00	$9.00
10mg	98%	in stock	$16.00	$11.00
50mg	98%	in stock	$45.00	$32.00
1g	98%	in stock	$706.00	$494.00
5g	98%	in stock	$2,059.00	$1,442.00

Description

• Catalog Number: AB24574
• Chemical Name: 4-({4-[(2,4,6-trimethylphenyl)amino]pyrimidin-2-yl}amino)benzonitrile
• CAS Number: 244767-67-7
• Molecular Formula: C20H19N5
• Molecular Weight: 329.3984
• MDL Number: MFCD09833899
• SMILES: N#Cc1ccc(cc1)Nc1nccc(n1)Nc1c(C)cc(cc1C)C

Computed Properties

• Complexity: 452
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 4
• XLogP3: 4.8

Literature

• Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.

  Bioorganic & medicinal chemistry letters 20130915

• Synthesis, evaluation and structure-activity relationships of triazine dimers as novel antiviral agents.

  Bioorganic & medicinal chemistry letters 20121201

• Interactions of microbicide nanoparticles with a simulated vaginal fluid.

  Molecular pharmaceutics 20121105

• Current status of topical antiretroviral chemoprophylaxis.

  Current opinion in HIV and AIDS 20121101

• Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine.

  Pharmaceutical research 20120601

• Testing of viscous anti-HIV microbicides using Lactobacillus.

  Journal of microbiological methods 20120201

• Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs).

  Bioorganic & medicinal chemistry 20111015

• Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.

  AIDS (London, England) 20110824

• Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.

  Journal of medicinal chemistry 20110428

• Complete inactivation of HIV-1 using photo-labeled non-nucleoside reverse transcriptase inhibitors.

  Virus research 20110101

• Update on microbicide research and development - seeking new HIV prevention tools for women.

  European journal of medical research 20110101

• Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy.

  Biochemical pharmacology 20101015

• Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel.

  Journal of acquired immune deficiency syndromes (1999) 20101001

• Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles.

  Journal of pharmaceutical and biomedical analysis 20100605

• Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20100219

• Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.

  Retrovirology 20100101

• Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

  Bioorganic & medicinal chemistry letters 20090915

• Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.

  Antimicrobial agents and chemotherapy 20090201

• Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.

  International journal of pharmaceutics 20061115

• Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.

  PLoS pathogens 20061101

• From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  Journal of medicinal chemistry 20050324

• In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

  Journal of medicinal chemistry 20050324

• TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

  Antimicrobial agents and chemotherapy 20041201

• A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.

  Antimicrobial agents and chemotherapy 20041001

• Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

  Journal of medicinal chemistry 20040506

• In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.

  Antimicrobial agents and chemotherapy 20040101

• Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors.

  Current topics in medicinal chemistry 20040101

• Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds.

  Drugs in R&D 20040101

• Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.

  Bioorganic & medicinal chemistry letters 20010903